Many oncologists have already adopted ceritinib as a second-line treatment for ALK-positive non–small cell lung cancer in patients who have developed resistance to crizotinib. The results of a randomized trial, presented at the European Society for Medical Oncology 2016 Congress, confirm that ceritinib is an effective option because it increases progression-free survival by 4 months over chemotherapy.
http://ift.tt/2gX3xgJ
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου